Candidate to Clinic Webinar and Q&A

Understanding the ADME (Absorption, Distribution, Metabolism, and Excretion) of drug candidates is crucial for successful drug discovery and development, particularly in oncology. As a drug candidate progresses towards clinical trials, comprehending its pharmaceutical properties becomes essential to ensure the formulation is efficient, safe and cost-effective.

In alignment with FDA’s Project Optimus which aims to reform dose optimisation and selection in oncology drug development, ApconiX and Seda PDS will share insights from our collaborative experiences in DMPK, toxicology and pharmaceutics. We aim to provide valuable knowledge on how these disciplines can address challenges, facilitate the design and discovery of new therapies and support both preclinical and clinical stages of drug development.

Join us for an engaging webinar where our team will answer your questions and discuss how our expertise can support your projects. This is an opportunity to gain deeper understanding and explore innovative solutions in drug development.

Register for this complimentary event here Hosted by Bionow

Ken is a DMPK specialist with a BSc in Biochemistry and an MSc in Biopharmacy. He has decades of experience in the pharmaceutical industry having worked for large companies (AstraZeneca and Rhône Poulenc [now Sanofi]) and small biotech (RedX Pharma) and CRO’s. During this time, Ken has managed or participated in many diverse projects covering bioanalysis, P450 inhibition, in vitro permeability, metabolic stability, ADME, in vivo pharmacokinetics and PK modelling. These projects have helped identify new drugs in oncology, cardiovascular, asthma, inflammation and anti-bacterial agents.

Ken has a keen interest in human predictive PK and its early application to identify potential drug candidates.

Linette is Chief Scientific Officer, bringing deep scientific leadership and strategic oversight to the company’s translational science efforts. She holds a BSc (Hons) from the University of Glasgow and a PhD in Chemistry from the University of Edinburgh.

With over 17 years at AstraZeneca, Linette built a distinguished career in Discovery and Early Pharmaceutical Development, where she led initiatives in physicochemical profiling, ADME and biopharmaceutics to guide compound design and selection. Her expertise spans in vitro, in silico, and in vivo models, supporting material choice and progression from discovery through to early clinical development.

In her current role, Linette drives the integration of DMPK/PD and biopharmaceutics insights into dose prediction, product design and clinical strategy, ensuring that scientific understanding translates into effective and patient-centric drug development.